Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.


Clinical Trial Description

This is a phase 3, open label, single arm, multi-center study in newly diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL patients who have myeloid or stem cell markers. The patients will receive decitabine combined with HAAG regimen in the induction treatment. The patients who respond to induction chemotherapy will undergo consolidation chemotherapy, and an optional allogeneic hematopoietic stem cell transplantation and post-transplantation maintenance treatment with decitabine according to patient's wishes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04446130
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Xiaowen Tang, Ph.D.
Phone (0086)51267781856
Email xwtang1020@163.com
Status Recruiting
Phase Phase 3
Start date January 1, 2019
Completion date January 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04539600 - Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer Phase 2
Recruiting NCT05397769 - Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. Phase 2
Completed NCT04473716 - Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients Phase 1
Recruiting NCT06093438 - Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Phase 1/Phase 2
Recruiting NCT02924909 - Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer Phase 2
Active, not recruiting NCT04384627 - Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Phase 3
Recruiting NCT05114707 - Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses Phase 2
Recruiting NCT04087967 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients Phase 3
Recruiting NCT04083911 - Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60 Phase 3